Back

Notification report


Full notification file


General information

Notification Number
B/GB/16/R49/01

Member State to which the notification was sent
United Kingdom

Date of acknowledgement from the Member State Competent Authority
09/12/2016

Title of the Project
A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54rgp140 combinations in order to maximise antibody responses to Human Immunodeficiency Virus

Proposed period of release:
01/04/2017 to 30/05/2020

Name of the Institute(s) or Company(ies)
Imperial College London, Department of Medicine, 4th Floor, Room 453
Medical School Building
St Mary’s Campus
Paddington
London
W2 1NY;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
The GMO to be used will be the study vaccine Ad4-EnvCN54, derived from the “parent wild type” Adenovirus serotype 4

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Adenovirus serotype 4AdenovirusAdenovirusMastadenovirusesSerotype 4Adenoviridae

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
07/03/2017 00:00:00
Remarks: